摘要
甲状腺乳头状癌(PTC)的发病率逐年上升,超声是其主要的检查手段,但部分PTC无典型超声影像学恶性征象,以及超声引导下细针穿刺细胞学诊断(FNAC)的局限性等原因,致术前无法获得明确诊断。近年来的研究倾向于寻找PTC发生、发展的关键分子,并应用于FNAC取样标本中进行检测,以提高PTC术前诊断准确率,为病情评估提供分子学依据。本文将对超声引导下FNAC联合丝/苏氨酸特异性激酶(BRAF)V600E基因突变检测诊断PTC及评估病情的研究进展进行综述。
The incidence of papillary thyroid cancer(PTC)has increased at an accelerating rate in recent years.Because of the lack of typical ultrasonic images and limitation of ultrasound-guided fine-needle aspiration cytology(FNAC)in some PTC,defining preoperative diagnosis could not be acquired sometimes.As a result,researchers tend to find the key molecule about the occurrence and development of PTC,and try to combine this molecule with ultrasound guided fine-needle aspiration cytology to improve the accuracy rate of preoperative diagnosis and to offer a molecular evidence for severity evaluation of PTC.This article reviews the research progress of BRAF V600E mutation detection combined with FNAC in papillary thyroid cancer diagnosis and severity evaluation.
作者
李若暄
慈霞
王菲
周祖邦
LI Ruoxuan;CI Xia;WANG Fei;ZHOU Zubang(Gansu University of Chinese Medicine,Lanzhou 730000,China)
出处
《临床超声医学杂志》
CSCD
2019年第5期366-368,共3页
Journal of Clinical Ultrasound in Medicine
基金
甘肃省人民医院院内科研基金项目(17GSSY6-11)
